The FDA has approved upadacitinib for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) based on a short-term study that demonstrated improved pain, function and other symptoms of nr-axSpA in patients with active disease.
Almost Half of Patients with RA Experience Flare after Glucocorticoid Discontinuation
In a post hoc analysis of two clinical trials, Maassen et al. demonstrated that 40% of patients with early RA or undifferentiated arthritis experienced disease flare after primary glucocorticoid discontinuation despite background treatment with conventional synthetic DMARDs.
ACR Leads AMA Resolution to Address Disruptive Practices of Pharmacy Benefit Administrators
At the AMA House of Delegates meeting in November, the ACR’s delegation will lead over a dozen cosponsoring specialties and medical associations in advancing a resolution addressing serious concerns about third-party pharmacy benefit administrators and the impacts of their disruptive practices.
November, a Busy Month for RheumPAC
In November, RheumPAC will be leading its annual matching campaign and hosting two events at ACR Convergence 2022. Thanks to matching donors, every contribution in November will be amplified.
Advocacy Highlights & Fall Treats: Reflections from the GAC Chair
Outgoing Government Affairs Committee Chair Blair Solow, MD, offers advocacy updates from 2022 and seasonal reflections on how to stay focused on efforts that matter when faced with daunting challenges.
ACR Honors Distinguished Fellows at ACR Convergence 2022
Editor’s note: This has been extended from the print version to include additional background information on each recipient. Each year, the ACR honors up to 10 clinical and research fellows who have performed meritoriously. Meet this year’s Distinguished Fellows, who are bridging the gap between research and patient care, and who were recognized at ACR…
With Deepest Gratitude: The ACR Appreciates Your Willing Service
We at the ACR acknowledge all ACR, ARP and Rheumatology Research Foundation volunteers whose committee terms are ending in November. Thank you for your valuable time and efforts toward advancing rheumatology during a challenging time. ACR: Board of Directors Kenneth G. Saag, MD, MSc; ACR President Barbara Slusher, MSW, PA-C; ARP President Anne R. Bass,…
Ankylosing Spondylitis: Treat to Target
This session at ACR Convergence 2022, on Monday, Nov. 14, 2022, from 9–10 a.m. EST, will examine guidelines and current evidence regarding the management and outcomes of patients with ankylosing spondylitis (AS). Alexis Ogdie, MD, a rheumatologist and associate professor of Medicine at the University of Pennsylvania, Philadelphia, will present data to highlight the evolution…
Changing Treatment Patterns for Patients with JIA
A study from Glerup et al. demonstrated that many patients with juvenile idiopathic arthritis achieved drug-free remission over 18 years of follow-up and that remission rates remained stable between years 8 and 18 of the study period.
Clinical Academic Rheumatology Generates Profits for Health Systems
Rheumatologists should be better compensated, in part, due to the revenue they bring to the hospital system from their procedures, argue D’Anna et al., who found that clinical academic rheumatologists bring significant downstream revenue to the healthcare system.
- « Previous Page
- 1
- …
- 86
- 87
- 88
- 89
- 90
- …
- 814
- Next Page »